Basilea Pharmaceutica AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 147
- Market Cap
- $676.7M
- Website
- http://www.basilea.com
Clinical Trials
52
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials
A Study of Fosmanogepix in Healthy Adult Chinese Subjects
- Conditions
- Healthy
- Interventions
- Drug: Oral FosmanogepixDrug: IV FosmanogepixDrug: oral placeboDrug: IV placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 54
- Registration Number
- NCT06961708
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Longchuan North Road, Shanghai, China
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
- Conditions
- Invasive Mold Infections
- Interventions
- Drug: Fosmanogepix IV infusionDrug: Standard of care antifungal therapyDrug: Fosmanogepix oral tablet
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 219
- Registration Number
- NCT06925321
- Locations
- 🇺🇸
Washington University School of Medicine, Infectious Diseases Clinical Research Unit, St Louis, Missouri, United States
A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin
- Conditions
- Drug-drug Interaction Study
- Interventions
- Drug: pitavastatin single dose combined with ceftobiprole
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 12
- Registration Number
- NCT06808646
- Locations
- 🇳🇱
ICON Early Clinical & Bioanalytical Solutions, Groningen, Netherlands
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
- Conditions
- Invasive Fungal Infections
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Basilea Pharmaceutica
- Registration Number
- NCT06433128
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 9
- Registration Number
- NCT05856227
- Locations
- 🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
🇧🇬MHAT Dr. Stamen Iliev AD Montana, Neonatology Department, Montana, Bulgaria
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
Basilea Pharmaceutica Acquires Global Rights to Phase 3-Ready Oral Antibiotic for Drug-Resistant UTIs
Basilea Pharmaceutica has entered an exclusive licensing agreement with Venatorx Pharmaceuticals to acquire global rights to ceftibuten-ledaborbactam etzadroxil, a novel oral antibiotic combination targeting complicated urinary tract infections.
Basilea Launches Phase 3 Trial for Novel Antifungal Fosmanogepix in Invasive Mold Infections
Basilea Pharmaceutica has initiated FORWARD-IM, a phase 3 registrational study evaluating fosmanogepix for treating invasive mold infections in adults, with completion expected in Q1 2028.
Basilea Secures $39 Million BARDA Funding to Advance Novel Antifungal Candidates Fosmanogepix and BAL2062
Basilea Pharmaceutica received $39 million in additional BARDA funding to continue development of novel antifungals fosmanogepix and BAL2062, bringing total committed funding to $68 million under a potential $268 million agreement.
Cresemba Antifungal Drug Achieves Record Global Sales, Triggers $2.5M Milestone Payment to Basilea
Basilea Pharmaceutica received a second $2.5 million milestone payment in 2025 from partner Pfizer following strong Cresemba sales performance in Asia Pacific and China.
FDA Approves Zevtera for S. aureus Bacteremia, Marking First New Treatment in 15 Years
Basilea Pharmaceutica's Zevtera (ceftobiprole) receives FDA approval for three indications, becoming the first beta-lactam antibiotic approved for Staphylococcus aureus bacteremia.
Basilea's Antibiotic BAL2420 Receives $7.3M CARB-X Funding to Combat Gram-Negative Infections
Basilea Pharmaceutica secures $7.3 million from CARB-X to advance BAL2420, a novel LptA inhibitor, towards first-in-human clinical trials by mid-2026.
Basilea's Fosmanogepix Enters Phase 3 for Invasive Candidiasis Treatment
Basilea Pharmaceutica has initiated a Phase 3 trial (FAST-IC) to assess fosmanogepix for treating candidemia and invasive candidiasis in adults.